Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich
Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101
NOTTINGHAM, England, Sept. 21, 2023 /PRNewswire/ -- A drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia's drug candidate EVX-101, which is in development for major depressive disorder (MDD).
Evecxia Therapeutics Announces CEO Transition
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that an oral presentation, “The Therapeutic Potential of EVX-101 to Amplify Serotonin Synthesis for the Adjunctive Treatment of MDD and Other Mental Illness: Emerging Profile and Post-Phase 1 Update”, will be presented during the Pharmaceutical Pipeline Session on May 30th by Dr. Jacobson, Chief Scientific Officer, at the 2023 ASCP Meeting in Miami Beach, FL.
Evecxia Therapeutics Receives Notice Of Allowance For A U.S. Patent Covering Its Lead Drug Candidate EVX?101
Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. The Company further announced the planned design of a Phase 2 adjunctive EVX-101 trial in patients with major depressive disorder (MDD) responding inadequately to a first-line antidepressant (selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)).
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing the therapeutic potential of serotonin synthesis amplification for the treatment of brain disorders, today announced that Joseph M. Patti, Ph.D., has been appointed President and Chief Executive Officer and a member of Evecxia’s board of directors. Dr. Patti brings extensive drug development and executive leadership expertise, including serving in multiple CEO roles, and as co-founder, Chief Scientific Officer and Senior Vice President of Research & Development of Inhibitex, Inc. until its $2.5 billion acquisition by Bristol Myers Squibb. Dr. Patti succeeds John J. Kaiser, who has retired but will continue to serve as a member of Evecxia’s board of directors.